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Selective protein unfolding: a universal mechanism of
action for the development of irreversible inhibitors†
Samuel Askin,a Thomas E. H. Bond,a Alanna E. Sorenson, a
Morgane J. J. Moreau,a Helma Antony,a Rohan A. Davis b and
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High-throughput differential scanning fluorimetry of GFP-tagged
proteins (HT-DSF-GTP) was applied for the identification of novel
enzyme inhibitors acting by a mechanism termed: selective protein
unfolding (SPU). Four different protein targets were interrogated
with the same library to identify target-selective hits. Several hits
selectively destabilized bacterial biotin protein ligase. Structure–
activity relationship data confirmed a structure-dependent mechanism
of protein unfolding. Simvastatin and altenusin were confirmed to
irreversibly inactivate biotin protein ligase. The principle of SPU
combined with HT-DSF-GTP affords an invaluable and innovative
workflow for the identification of new inhibitors with potential
applications as antimicrobials and other biocides.
Enzyme inhibitors are invaluable for the development of drugs,
herbicides and pesticides. The potency and specificity of inhibitors
are key to their successful applications in modern medicine and
agriculture. Inhibitors can be either reversible or irreversible.
Reversible inhibitors bind non-covalently to the target through a
variety of mechanisms e.g. competitive, uncompetitive, non-
competitive and mixed inhibition. Irreversible inhibitors often
react with the enzyme via covalent bond formation. In the last
decades very few fundamentally new mechanisms of inhibition
leading to inactivation of protein targets have been discovered. A
new mechanism of action was recently unveiled for nucleozin, a
potent inhibitor of the influenza nucleoprotein.1 Nucleozin
aggregates nucleoprotein rendering its packaging in the virus
impossible.2 Destabilizing compounds are commonly dismissed
as they are assumed to be non-specific (e.g. chaotropic agents) but
a few studies have shown that organometallic complexes3,4 and
nanoparticles5 can selectively destabilize proteins. Other systems
such as PROTAC can flag target proteins to the proteasome.6,7
DSF and DSF-GTP are perfectly suited to screen compounds in
high-throughput (HT) by measuring their effect on the thermal
stability of a target protein.8–10
In this work we screened an identical library of 940 compounds
with four different proteins in order to identify target selective hits
(Fig. 1 and Fig. S1, ESI†). We used HT-DSF-GTP to compare the
effect of each compound on the thermal stability of E. coli (Ec)
biotin protein ligase11 (BirA), dengue virus RNA-dependent RNA
polymerase9 (RdRp), the putative replicative DNA helicase (DnaB)
and primase (DnaG)12 of Burkholderia pseudomallei (Bp).
All targets were produced as fusion proteins including both
N-terminal hexahistidine and C-terminal GFP tags as previously
Fig. 1 HT DSF-GTP screening of 940 pure compounds with Ec BirA-GFP.
Compounds (1 mL at 5 mM in DMSO, Compounds Australia) were dis-
pensed in 96-well clear PCR plates (Biorad, HSP9601). Ec BirA-GFP (49 mL
at 1 mM) was added to each compound for 15 min at RT prior subjecting the
reactions to a melt-curve protocol (30–85 1C at 0.5 1C/30 s) in a IQ5
iCycler (Bio-Rad). Tm were analyzed as previously described.
10 Structures
of selected compounds and respective DTm are shown. See ESI,† for
detailed methods and Fig. S1 and S2A for extended data.
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described for RdRp-GFP, Bp DnaG-GFP,9 and BirA-GFP.11 Proteins
(1 mM) were reacted with compounds (100 mM) in 96-well PCR
plates for 15 min at room temperature before subjecting the
reactions to a melt-curve protocol in a real-time PCR cycler
(Fig. 1 and Fig. S1, ESI†). Transition midpoint (Tm) values were
recorded and processed as described previously using an auto-
mated Tm peak recognition software.
10 For each compound, the
net change in Tm (DTm) was determined by subtracting the Tm
of ‘Target-GFP’ from the Tm of ‘Target-GFP + compound’ in identical
buffer conditions. After the initial screen (801 compounds from
Open Collection (Scaffolds) and 139 from Open Access Natural
Product-Based Library, Compounds Australia) it became evident
that of the compounds that affected a protein, the majority
decreased the proteins’ Tm. This is particularly obvious for Ec
BirA-GFP (Fig. 1). From the initial screen, 94 hits were identified
(i.e. the most stabilizing or destabilizing hits) and rescreened
with all four targets to evaluate the reproducibility of the assay.
Only four compounds that produced no distinguishable peak in
the first screen were subsequently identified in the second
screen.
The study was focussed on the hits identified in the Ec BirA-GFP
screen as they had the largest effect on protein stability. A positive
DTm cut-off value was set to +3 1C which is equal to the increase in
Tm of Ec BirA-GFP in the presence of 2 mM of biotin.
11
We also set a negative DTm cut-off value at 7 1C due to the
high number of destabilizing compounds identified for Ec
BirA-GFP. Eleven selective hits were identified, with only one
hit that significantly increased Ec BirA-GFP’s Tm (Fig. 1 and 2A).
The remaining 10 compounds thermally destabilized Ec BirA-GFP
between 7 and 11 1C. These hits do not affect GFP (internal
control) suggesting a target selective destabilizing mechanism.
This is further supported by the fact that the remaining targets
were mostly unaffected although in a different buffer. After
rescreening and identification of false positives no compound
destabilized GFP or any of the remaining protein targetsZ5 1C
(see ESI,† Fig. S1).
The distribution of DTm values obtained for Ec BirA-GFP
(Fig. 2A) shows that the majority of compounds does not
significantly affect the Tm of Ec BirA-GFP (i.e. 2 1C) with
maximal effects recorded between 11 and +4.5 1C (Fig. 2A).
Only one stabilizing hit 1 (DTm = +4.5 1C) was identified with a
MW of 341 and log P value of 0.9 (Fig. 1 and 2B). No Ec BirA-GFP
Tm peak was observed with structural analogues 2 and 3 (Fig. 1).
For destabilizing hits, a clear correlation can be seen between
increasing MW and log P values, and decreasing Tm (Fig. 2B).
Destabilizing compounds are commonly written off as being
non-specific. Strikingly, several of the Ec BirA selective destabilizing
compounds were either serrulatanes13 4a–e (Fig. 1 and Fig. S2B,
ESI†) or tetrahydroanthraquinones14,15 5a–l (Fig. 1 and Fig. S2C,
ESI†) suggesting a structure-specific mechanism of protein
destabilization. The strong structure–activity relationship (SAR)
and striking correlation between the logP and MW of Ec BirA
selective destabilizing compounds lead us to hypothesize that
they may present an untapped source of inhibitors.
First, we examined the concentration dependence of Ec
BirA-GFP hits (see Fig. 3A and Fig. S3A, ESI†), including
stabilizing hit 1; destabilizing hits 2 and 3 which eliminated
the Tm peak of Ec BirA, RdRp and Bp DnaG; serrulatanes 4a and
4b; 6; mitchellene B16 7, casticin 8, altenusin 9, lovastatin 10a,
11; and inactive compound Ia (see ESI,† Fig. S2A–D). All hits
reduced the Tm of Ec BirA-GFP in a concentration-dependent
fashion including 2 and 3 highlighting that for these the loss of
Tm peak was due to protein unfolding at 100 mM.
Next, we examined SAR of four Ec BirA-GFP selective hits
and four inactive compounds (see Fig. 3B and ESI,† Fig. S3B for
extended data). For each selected compound, we tested ten
structural analogues on Ec BirA-GFP’s Tm (V1–V10). No analogue
of 1 and 6 affected Ec BirA-GFP but several analogues of both 11
and 12 significantly decreased its Tm (DTm range: 3.25 to
6.75 1C; see ESI,† Fig. S2A and S3B). Finally, with the exception
of two analogues of inactive compound Ib (see Fig. S2D and S3B,
ESI†) being slightly destabilizing (r2 1C), none of the others
affected Ec BirA-GFP. The data supported that target selectivity
of destabilizing hits is structure dependent.
Lovastatin 10a, a HMG CoA reductase inhibitor was identified
as a Ec BirA-GFP destabilizing hit (DTm = 7 1C) in the initial
screen. 10a was only little to moderately destabilizing towards
DnaG-, DnaB- and RdRp-GFP (ESI,† Fig. S1B). Simvastatin 10b
(Fig. 4) has broad antimicrobial activity against various Gram-
positive pathogens and is also active against several Gram-
negative pathogens e.g. Ec, Acinetobacter baumannii, Salmonella
typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa
with MIC ranging from 8–32 mg mL1 when their outer
Fig. 2 (A) Statistical distribution of Ec BirA-GFP stabilizing and destabilizing
compounds. (B) Correlation between logP and MW of compounds, and
their effect on Ec BirA-GFP Tm.
Fig. 3 Concentration dependence (A) and SAR studies (B). (A) Effect of
two-fold serially diluted compounds on Ec BirA-GFP Tm. One inactive
compound Ia (see ESI,† Fig. S2D) and eleven hits were selected from the
initial screen. Only four compounds are shown for clarity (see ESI,† Fig. S3A
for full data). (B) Effect of scaffold analogues on Ec BirA-GFP Tm. For each
selected inactive compound and hits (Open Collection Scaffolds Library),
ten analogues (V1–V10) were tested. The same four compounds are
shown in panel A and B for clarity (see ESI,† Fig. S3B for full data).
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membrane permeability is compromised using sub-inhibitory
concentrations of colistin.17 This prompted us to perform a small
scale statin-focussed SAR study. For this, 10a, 10b, pravastatin
10c and fluvastatin 10d were tested on Ec BirA-GFP (Fig. 4 and
Fig. S2A, ESI†). 10a, 10b and 10d destabilized Ec BirA-GFP,
however 10b was more potent at lower concentrations and 10d
was the least potent. 10c, an open lactone form, did not
destabilize Ec BirA-GFP. This observation suggests an important
role for the lactone ring of statins in BirA destabilization. It is
important to note that a methyl to hydroxyl group substitution
in 10c could also be the cause of its inactivity. With 10d, it is
more difficult to draw any parallel conclusions as its structure is
very different to the three other statins (see ESI,† Fig. S2A).
Nevertheless we can hypothesize that the polyaromatic ring
structure of 10d is most likely responsible for Ec BirA-GFP
destabilization rather than its open lactone structure, and that
its protein binding site is thus different to the site of binding of
10a and 10b.
Statins were further investigated with GFP-Basta18 in iso-
thermal reactions to assess if they induce BirA aggregation
(Fig. 5A). Ec BirA-GFP (1 mM) was reacted with statins (100 mM)
in the presence of biotin, ATP and MgCl2 for 30 min at 37 1C
before centrifugation and quantification of the soluble fluores-
cent protein fraction (Ffold) by fluorimetry of the GFP domain
(see ESI,† for detailed methods). 10b was most destabilizing,
leading toB70% protein aggregation after 10 min incubation at
37 1C followed by 10a. Neither 10c nor 10d caused significant
aggregation of Ec BirA-GFP over 30 min in these conditions. 10a
and 10b were further tested on two orthologous BirA, i.e. Bp and
Mycobacterium tuberculosis (Mt) BirA-GFP.19,20 These proteins
shareB30% sequence identity with each other and the Ec BirA.
Both statins showed very little effect on Mt BirA-GFP at 100 mM
(DTm = 2 1C) and moderate destabilizing effects on Bp BirA-GFP
(cf. ESI,† Fig. S4A) revealing a preferential destabilizing effect of
10a and 10b on Ec BirA. Using a GFP-based biotinylation activity
assay,11,21 we confirmed that 10b leads to Ec BirA-GFP inactivation
(Fig. 5B). For this, Ec BirA-GFP was pre-incubated at 37 1C with 10b
or 10c for 1 h prior addition of the GFP-AviTag substrate and
biotinylation reaction. Under these conditions, 10b inhibited Ec
BirA-GFP activity by 83% (Fig. 5B, see ESI,† for detailed methods).
As expected, 10c did not affect Ec BirA-GFP. Taken together, the
data show that inhibition of biotinylation activity is associated with
10b-induced unfolding and aggregation of Ec BirA-GFP.
Altenusin 9 was identified as a potent and highly selective Ec
BirA-GFP destabilizing hit (DTm = 8.5 1C). Indeed, 9 showed
no effect on any other proteins (Fig. S1B, ESI†). It has previously
been shown to exert broad antimicrobial activity against several
multidrug-resistant bacterial and fungal strains albeit not
against Ec.22,23 Concentration dependence curves for Ec and
the two orthologous Bp and Mt BirA-GFP showed that 9 was Ec
selective. Only a small destabilizing effect was observed with Bp
and Mt BirA-GFP in the presence of 100 mM of 9 (Fig. 6A and
Fig. S4B, ESI†). The data clearly demonstrate that 9 inactivates
Ec BirA-GFP at 25 1C (Fig. 6B, see ESI,† for detailed methods)
through a highly selective protein unfolding (SPU) mechanism.
Target engagement in the cell24 as well as non-specific
binding to serum proteins25 are major hurdles in drug develop-
ment. We examined if 9, 10a and 10b were able to exert their
destabilizing effect in a clarified bacterial cell lysate and in
human serum (see ESI,† for detailed methods). DSF-GTP is the
only DSF method that can selectively measure the Tm of a protein
in the presence of other protein contaminants. DSF-GTP is thus
perfectly suited for target engagement and serum interaction
studies. All hits lost their ability to destabilize Ec BirA-GFP in the
bacterial lysate even after heat treatment (95 1C for 5 min) and
clarification (see ESI,† Fig. S5). Since heat treatment denatures all
but the most thermostable proteins, the loss of destabilizing
activity could be due to a non-proteinaceous soluble factor in the
bacterial lysate. In serum, significant differences in Ec BirA-GFP
Fig. 4 SAR and concentration dependence of statins 10a–d on Tm of Ec
BirA-GFP. Error bars represent SD (N = 2). See ESI,† Fig. S2A for structure
of 10d.
Fig. 5 Effect of statins on aggregation and biotinylation activity of Ec
BirA-GFP. (A) Isothermal aggregation reactions18 were performed at 37 1C
with statins 10a–d at 100 mM. Soluble fluorescent protein fraction (Ffold)
was determined by measuring residual fluorescence of Ec BirA-GFP in
the reaction supernatant after centrifugation. Control reactions were
performed without a statin. Error bars represent SD (N = 2). (B) Inhibition
of Ec BirA-GFP biotinylation activity by 10b and 10c at 37 1C. Inhibition
of GFP-AviTag substrate biotinylation was determined by streptavidin
(Stv)-induced band-shift and SDS-PAGE analysis.11 See Fig. 4 for structures
of statins and ESI,† for detailed methods.
Fig. 6 (A) Concentration dependence of 9 on Tm of Ec, Bp and Mt BirA-
GFP. Melt-curve protocol: 25–85 1C at 0.5 1C/30 s. Error bars represent SD
(N = 2). (B) Inhibition of Ec BirA-GFP biotinylation activity by 9 at 25 1C (see
Fig. 5B and ESI,† for detailed methods).11
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Tm were observed with the three different control reactions, with
the heat-treated serum being the most destabilizing condition
(see ESI,† Fig. S5). This suggest that one or more factors
generated in the heat-treated serum are significantly affecting
the Tm of Ec BirA-GFP. The heat-inducible destabilizing factor(s)
can be partially eliminated after clarification of the heat-treated
serum suggesting an aggregated proteinaceous factor. Most
importantly and in stark contrast with the statins, 9 significantly
destabilised Ec BirA-GFP in human serum. This effect is most
pronounced in the heat treated and clarified serum (ESI,†
Fig. S5).
10b has been shown to display a multitude of biological
activities and clearly promiscuously binds several protein targets.
In Staphylococcus aureus (SA), 10b significantly inhibits DNA,
protein and lipid synthesis and to a lesser extent RNA synthesis
and cell wall synthesis.17 BirA is the sole enzyme responsible for
covalently attaching biotin at the active site of important meta-
bolic enzymes, the biotin carboxylase and decarboxylases.26 The
biotin carboxylases are essential enzymes in gluconeogenesis,
lipogenesis, amino acid metabolism and energy transduction.
Although the two orthologous Mt20 and Bp19 BirA tested in this
study were not significantly destabilized by 10b, it is important to
note they are both type I enzymes whereas Ec BirA is a type II
enzyme like Sa BirA.27 Thus, it is still tempting to propose BirA as
a major target of 10b in susceptible bacteria whose inactivation
would lead to a systematic inhibition of metabolic processes such
as in Sa.17 The fact that the bacterial lysate abolished the
destabilizing activity of 10b on Ec BirA-GFP could indicate that
it binds to further targets present in the bacteria or released after
lysis. The high MIC value of 10b limits its use as a topical agent17
which is supported by our data in serum. Whether the anti-
bacterial activity of 9 could also be improved against Gram-
negative bacteria with the help of sub-inhibitory concentrations
of colistin remains to be tested. Nevertheless, if entry of 9 into the
bacteria can be achieved, and based on its activity in serum as well
as its moderate cytotoxicity, it could become a promising lead.
Overall, our data clearly demonstrate that protein destabilizing
compounds can be target- and species-selective (ESI,† Fig. S1B and
Fig. 6A), and thus may offer quality lead compounds with applica-
tions in various fields of life sciences. Our data also highlight the
unique application of HT DSF-GTP for screening protein–ligand
interactions in complex matrices and identifying non-promiscuous
hits. SPU as amechanism of action combined with the power of HT
DSF-GTP offers a fast and efficient platform for screening and
identifying an exciting class of new inhibitors.
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